Core Laboratories Inc (NYSE: CLB) has a price-to-earnings ratio that is above its average at 31.65x. The stock has a 36-month beta value of 2.40. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for CLB is 46.44M, and at present, short sellers hold a 17.65% of that float. On August 23, 2024, the average trading volume of CLB was 479.66K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CLB) stock’s latest price update
The stock price of Core Laboratories Inc (NYSE: CLB) has surged by 2.60 when compared to previous closing price of 18.11, but the company has seen a -4.67% decline in its stock price over the last five trading sessions. zacks.com reported 2024-07-31 that Investors interested in stocks from the Oil and Gas – Field Services sector have probably already heard of Baker Hughes (BKR) and Core Laboratories (CLB). But which of these two companies is the best option for those looking for undervalued stocks?
CLB’s Market Performance
Core Laboratories Inc (CLB) has experienced a -4.67% fall in stock performance for the past week, with a -23.70% drop in the past month, and a 2.48% rise in the past quarter. The volatility ratio for the week is 3.09%, and the volatility levels for the past 30 days are at 4.21% for CLB. The simple moving average for the last 20 days is -10.69% for CLB stock, with a simple moving average of 3.72% for the last 200 days.
Analysts’ Opinion of CLB
Many brokerage firms have already submitted their reports for CLB stocks, with Citigroup repeating the rating for CLB by listing it as a “Sell.” The predicted price for CLB in the upcoming period, according to Citigroup is $21 based on the research report published on June 30, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see CLB reach a price target of $21.50. The rating they have provided for CLB stocks is “Underperform” according to the report published on April 18th, 2023.
CLB Trading at -10.44% from the 50-Day Moving Average
After a stumble in the market that brought CLB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.85% of loss for the given period.
Volatility was left at 4.21%, however, over the last 30 days, the volatility rate increased by 3.09%, as shares sank -22.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.70% upper at present.
During the last 5 trading sessions, CLB fell by -4.16%, which changed the moving average for the period of 200-days by -8.21% in comparison to the 20-day moving average, which settled at $20.53. In addition, Core Laboratories Inc saw 5.21% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CLB
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.18 for the gross margin
The net margin for Core Laboratories Inc stands at 0.05. The total capital return value is set at 0.11. Equity return is now at value 12.29, with 4.66 for asset returns.
Based on Core Laboratories Inc (CLB), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.66. The interest coverage ratio of the stock is 3.95.
Currently, EBITDA for the company is 69.57 million with net debt to EBITDA at 2.69. When we switch over and look at the enterprise to sales, we see a ratio of 2.05. The receivables turnover for the company is 3.93for trailing twelve months and the total asset turnover is 0.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.39.
Conclusion
To sum up, Core Laboratories Inc (CLB) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
